Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Strasser-Fuchs, S; Fazekas, F.
Immunoglobulin in neurologic disorders
AKTUEL NEUROL. 2000; 27: 268-272.
Doi: 10.1055/s-2007-1017553
Web of Science
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Fazekas Franz
- Fuchs Siegrid
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Intravenous immunoglobulin (IVIG) is a promising immunomodulatory substance and scientific evidence for its successful use in various neurologic autoimmune diseases has increased over the past years. However, IVIG should only be given with great responsibility because of its limited availability as a biologic product, possible side effects and potentially high costs. Based on extensive documentation of equal effectiveness with plasmapheresis in parallel with easier application IVIG can currently be considered as first line therapy of the Guillain-Barre syndrome. In the absence of other therapeutic options the same is true for multifocal motor neuropathy. IVIG is an important therapeutic alternative in chronic inflammatory demyelinating polyneuropathy and dermatomyositis, and in the future IVIG may play a similar role in the treatment of multiple sclerosis and myasthenia gravis. For confirmation of the efficacy of IVIG in latter disorders and to optimize respective treatment regimen further well controlled trials are needed.